Related Experiment Video

Updated: Jan 3, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.8K

Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure

Claudio Borghi1,2, Alberto Palazzuoli3, Matteo Landolfo4

  • 1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. claudio.borghi@unibo.it.

Heart Failure Reviews
|November 21, 2019
PubMed

Insights

High uric acid levels (hyperuricemia) are linked to cardiovascular diseases, especially heart failure. Lowering uric acid may improve heart failure prognosis, warranting further investigation into management strategies.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Nephrology

Background:

  • Uric acid is a metabolic byproduct linked to gout and kidney stones.
  • Hyperuricemia, or elevated uric acid, is increasingly recognized as a metabolic disorder.
  • Uric acid levels correlate with cardiovascular diseases like hypertension, myocardial infarction, metabolic syndrome, and heart failure.

Purpose of the Study:

  • To review the pathophysiology of hyperuricemia.
  • To explore the biological mechanisms linking uric acid to cardiovascular disorders.
  • To focus on hyperuricemia's role in heart failure onset and progression.

Main Methods:

  • Literature review of existing studies on uric acid and cardiovascular disease.
  • Analysis of pathophysiological pathways involved in hyperuricemia.
  • Examination of clinical data on heart failure and uric acid levels.

Main Results:

  • Hyperuricemia is biologically plausible to contribute to cardiovascular pathogenesis.
  • Specific focus on the implications of hyperuricemia in heart failure development and worsening.
  • Review of data on drug classes affecting uric acid levels and their impact on heart failure.

Conclusions:

  • Hyperuricemia is implicated in the pathophysiology of cardiovascular disorders, particularly heart failure.
  • Understanding these links can inform clinical practice and patient outcomes.
  • Lowering plasma uric acid may offer a therapeutic target for improving heart failure prognosis.

Keywords:
Cardiovascular diseasesHeart failureUric acidXanthine oxidase

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.9K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.1K

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
757
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
633
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
633
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
184
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
857